Pressurized intraperitoneal aerosol chemotherapy with oxaliplatin in colorectal peritoneal metastasis
Open Access
- 2 April 2016
- journal article
- research article
- Published by Wiley in Colorectal Disease
- Vol. 18 (4), 364-371
- https://doi.org/10.1111/codi.13130
Abstract
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an experimental drug delivery method that applies chemotherapy into the abdominal cavity as an aerosol under pressure. We present the first results obtained with PIPAC in colorectal peritoneal metastasis (CPM). This is a retrospective analysis. PIPAC was applied in 17 consecutive patients with pretreated CPM. All patients had previously undergone surgery, and 16 had undergone previous lines of systemic chemotherapy (median, two lines). The mean peritoneal metastasis index (peritoneal cancer index) was 16 ± 10. Forty-eight applications of PIPAC with oxaliplatin (92 mg/m2 ) were given every 6 weeks at 37 °C and 12 mmHg for 30 min. The outcome criteria were microscopic pathological response, survival and adverse events according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Forty-eight PIPAC administrations were performed with no intra-operative complications. The mean number of PIPAC administrations per patient was 2.8 (minimum one, maximum six). Postoperative adverse events (CTCAE level 3) were observed in four patients (23%), no CTCAE level-4 adverse events were reported. The hospital mortality was zero. Objective tumour responses were observed in 12/17 patients (71%), and the overall responses were as follows: complete pathological response (seven patients), major response (four patients), partial response (one patient), no response (two patients) and not eligible (three patients). The mean survival after first PIPAC was 15.7 months. Repeated PIPAC with oxaliplatin can induce the regression of pretreated CPM. The toxicity appears to be low. These preliminary results are encouraging and justify prospective clinical studies.Keywords
This publication has 21 references indexed in Scilit:
- The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgeryJournal of Surgical Oncology, 2014
- Description of a novel approach for intraperitoneal drug delivery and the related deviceSurgical Endoscopy, 2012
- A Phase II Study of Modified FOLFOX4 for Colorectal Cancer Patients with Peritoneal CarcinomatosisCancer Research and Treatment, 2011
- Evaluation of Best Supportive Care and Systemic Chemotherapy as Treatment Stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for Peritoneal Carcinomatosis of Colorectal OriginBMC Cancer, 2010
- Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal CancerJournal of Clinical Oncology, 2003
- Peritoneal carcinomatosis from colorectal cancerBritish Journal of Surgery, 2002
- Peritoneal carcinomatosis from non-gynecologic malignanciesCancer, 2000
- Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisatorSurgical Endoscopy, 2000
- Pharmacokinetic Problems in Peritoneal Drug Administration: Tissue Penetration and Surface ExposureJNCI Journal of the National Cancer Institute, 1997
- Peritioneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factorsCancer, 1989